Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity
Chien-Chun Steven Pai, … , Gillian Kingsbury, Lawrence Fong
Chien-Chun Steven Pai, … , Gillian Kingsbury, Lawrence Fong
Published December 10, 2018
Citation Information: J Clin Invest. 2019;129(1):349-363. https://doi.org/10.1172/JCI123391.
View: Text | PDF
Research Article Immunology Oncology Article has an altmetric score of 22

Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity

  • Text
  • PDF
Abstract

While immune checkpoint blockade leads to potent antitumor efficacy, it also leads to immune-related adverse events in cancer patients. These toxicities stem from systemic immune activation resulting in inflammation of multiple organs, including the gastrointestinal tract, lung, and endocrine organs. We developed a dual variable domain immunoglobulin of anti-CTLA4 antibody (anti-CTLA4 DVD, where CTLA4 is defined as cytotoxic T lymphocyte–associated antigen-4) possessing an outer tumor-specific antigen-binding site engineered to shield the inner anti-CTLA4–binding domain. Upon reaching the tumor, the outer domain was cleaved by membrane type-serine protease 1 (MT-SP1) present in the tumor microenvironment, leading to enhanced localization of CTLA4 blockade. Anti-CTLA4 DVD markedly reduced multiorgan immune toxicity by preserving tissue-resident Tregs in Rag 1–/– mice that received naive donor CD4+ T cells from WT C57BL/6j mice. Moreover, anti-CTLA4 DVD induced potent antitumor effects by decreasing tumor-infiltrating Tregs and increasing the infiltration of antigen-specific CD8+ T lymphocytes in TRAMP-C2–bearing C57BL/6j mice. Treg depletion was mediated through the antibody-dependent cellular cytotoxicity (ADCC) mechanism, as anti-CTLA4 without the FcγR-binding portion (anti-CTLA4 DANA) spared Tregs, preventing treatment-induced toxicities. In summary, our results demonstrate an approach to anti-CTLA4 blockade that depletes tumor-infiltrating, but not tissue-resident, Tregs, preserving antitumor effects while minimizing toxicity. Thus, our tumor-conditional anti-CTLA4 DVD provides an avenue for uncoupling antitumor efficacy from immunotherapy-induced toxicities.

Authors

Chien-Chun Steven Pai, Donald M. Simons, Xiaoqing Lu, Michael Evans, Junnian Wei, Yung-hua Wang, Mingyi Chen, John Huang, Chanhyuk Park, Anthony Chang, Jiaxi Wang, Susan Westmoreland, Christine Beam, Dave Banach, Diana Bowley, Feng Dong, Jane Seagal, Wendy Ritacco, Paul L. Richardson, Soumya Mitra, Grace Lynch, Pete Bousquet, John Mankovich, Gillian Kingsbury, Lawrence Fong

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2020 2019 2018 2009 Total
Citations: 1 9 11 25 11 13 4 1 1 76
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (76)

Title and authors Publication Year
Impact of tumor localization on antitumor immunity with conditionally activated CTLA-4 blockade
Arias-Badia M, Pai CC, Lwin YM, Chen P, Srinath A, Tanaka M, Musser E, Goodearl A, Gorman JV, Ritacco W, Fong L
Journal for Immunotherapy of Cancer 2025
Emerging mechanisms of the unfolded protein response in therapeutic resistance: from chemotherapy to Immunotherapy.
He J, Zhou Y, Sun L
Cell communication and signaling : CCS 2024
Machine learning reveals diverse cell death patterns in lung adenocarcinoma prognosis and therapy
Wang S, Wang R, Hu D, Zhang C, Cao P, Huang J
npj Precision Oncology 2024
The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling
Li T, Niu M, Zhou J, Wu K, Yi M
Cell communication and signaling : CCS 2024
Prognostic prediction using a gene signature developed based on exhausted T cells for liver cancer patients
Zhou Y, Wu W, Cai W, Zhang D, Zhang W, Luo Y, Cai F, Shi Z
Heliyon 2024
CD155-TIGIT Axis as a Therapeutic Target for Cancer Immunotherapy.
Mu Y, Guan X
Current medicinal chemistry 2024
Efficacy and advantage of immunotherapy for melanoma via intramuscular co-expression of plasmid-encoded PD-1 and CTLA-4 scFvs
Yang Y, Huang Q, Cheng M, Deng L, Liu X, Zheng X, Wei J, Lei Y, Li X, Guo F, Deng Y, Zheng Y, Bi F, Wang G, Liu M
American journal of cancer research 2024
Targeting cytotoxic lymphocyte antigen 4 (CTLA-4) in breast cancer
Jama M, Tabana Y, Barakat KH
European Journal of Medical Research 2024
Multiple omics integrative analysis identifies GARS1 as a novel prognostic and immunological biomarker: from pan-cancer to bladder cancer.
Liu W, Wei C, He Q, Chen Z, Zhuang W, Guo Y, Xue X
Scientific reports 2024
Evolution of myeloid-mediated immunotherapy resistance in prostate cancer
Lyu A, Fan Z, Clark M, Lea A, Luong D, Setayesh A, Starzinski A, Wolters R, Arias-Badia M, Allaire K, Wu K, Gurunathan V, Valderrábano L, Wei XX, Miller RA, Van Allen EM, Fong L
Nature 2024
Oxidative stress in the tumor microenvironment in gastric cancer and its potential role in immunotherapy
Yu Y, Wu Y, Zhang Y, Lu M, Su X
FEBS Open Bio 2023
Microfluidics‐Enabled Nanovesicle Delivers CD47/PD‐L1 Antibodies to Enhance Antitumor Immunity and Reduce Immunotoxicity in Lung Adenocarcinoma
Su Z, Dong S, Chen Y, Huang T, Qin B, Yang Q, Jiang X, Zou C
Advanced Science 2023
Therapeutic Targets of Monoclonal Antibodies Used in the Treatment of Cancer: Current and Emerging
Effer B, Perez I, Ulloa D, Mayer C, Muñoz F, Bustos D, Rojas C, Manterola C, Vergara-Gómez L, Dappolonnio C, Weber H, Leal P
Biomedicines 2023
Systemic treatments for resectable carcinoma of the esophagus
Leowattana W, Leowattana P, Leowattana T
World Journal of Gastroenterology 2023
Therapeutic antibodies for precise cancer immunotherapy: current and future perspectives
Liu L, Chen J
2023
Stocking the Toolbox – Using Preclinical Models to Understand the Development and Treatment of Immune Checkpoint Inhibitor-induced Immune-Related Adverse Events
Cina M, Venegas J, Young A
Immunological Reviews 2023
Cancer stem cell-derived CHI3L1 activates the MAF/CTLA4 signaling pathway to promote immune escape in triple-negative breast cancer
Ji S, Yu H, Zhou D, Fan X, Duan Y, Tan Y, Lang M, Shao G
Journal of Translational Medicine 2023
Intratumoral nanofluidic system enhanced tumor biodistribution of PD‐L1 antibody in triple‐negative breast cancer
Liu H, Capuani S, Badachhape AA, Di Trani N, Davila Gonzalez D, Vander Pol RS, Viswanath DI, Saunders S, Hernandez N, Ghaghada KB, Chen S, Nance E, Annapragada AV, Chua CY, Grattoni A
Bioengineering & Translational Medicine 2023
Bioinformatics-based analysis of the relationship between disulfidptosis and prognosis and treatment response in pancreatic cancer.
Xiong Y, Kong X, Mei H, Wang J, Zhou S
Scientific Reports 2023
The role of macrophages in gastric cancer
Zhang J, Hu C, Zhang R, Xu J, Zhang Y, Yuan L, Zhang S, Pan S, Cao M, Qin J, Cheng X, Xu Z
Frontiers in immunology 2023
XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer
Jenkins KA, Park M, Pederzoli-Ribeil M, Eskiocak U, Johnson P, Guzman W, McLaughlin M, Moore-Lai D, O\u2019Toole C, Liu Z, Nicholson B, Flesch V, Qiu H, Clackson T, O\u2019Hagan RC, Rodeck U, Karow M, O\u2019Neil J, Williams JC
Journal for ImmunoTherapy of Cancer 2023
Aging-associated and CD4 T cell-dependent ectopic CXCL13 activation predisposes to anti-PD-1 therapy-induced adverse events
Hirotake Tsukamoto, Yoshihiro Komohara, Yusuke Tomita, Yuji Miura, Takanobu Motoshima, Kosuke Imamura, Toshiki Kimura, Tokunori Ikeda, Tomomi Kamba, Takuro Sakagami, Hiroyuki Oshiumi
Proceedings of the National Academy of Sciences 2022
Role of Serine Proteases at the Tumor-Stroma Interface
R Tagirasa, E Yoo
Frontiers in immunology 2022
Determining the Prognostic Value of Spliceosome-Related Genes in Hepatocellular Carcinoma Patients
J Liu, L Gu, D Zhang, W Li
Frontiers in Molecular Biosciences 2022
SIRT7 is a Prognostic Biomarker in Kidney Renal Clear Cell Carcinoma That is Correlated with Immune Cell Infiltration
W Zhang, Y Qian, X Jin, Y Wang, L Mu, Z Jiang
International journal of general medicine 2022
Application of Regulatory Cell Death in Cancer: Based on Targeted Therapy and Immunotherapy
X Qi, Q Li, X Che, Q Wang, G Wu
Frontiers in immunology 2022
A tumor-specific pro-IL-12 activates preexisting cytotoxic T cells to control established tumors
D Xue, B Moon, J Liao, J Guo, Z Zou, Y Han, S Cao, Y Wang, Y Fu, H Peng
Science Immunology 2022
Single-Cell Sequencing Identifies the Heterogeneity of CD8+ T Cells and Novel Biomarker Genes in Hepatocellular Carcinoma.
Wang H, Fu Y, Da BB, Xiong G
Journal of Healthcare Engineering 2022
Immunotherapy: Reshape the Tumor Immune Microenvironment.
Lv B, Wang Y, Ma D, Cheng W, Liu J, Yong T, Chen H, Wang C
Frontiers in immunology 2022
Oncolytic Activity of a Chimeric Influenza A Virus Carrying a Human CTLA4 Antibody in Hepatocellular Carcinoma
Yang H, Lei G, Sun F, Cheng J, Yan J, Zhang S, Yang P
Frontiers in Oncology 2022
Prodrug-Activating Chain Exchange (PACE) converts targeted prodrug derivatives to functional bi- or multispecific antibodies
Dickopf S, Buldun C, Vasic V, Georges G, Hage C, Mayer K, Forster M, Wessels U, Stubenrauch KG, Benz J, Ehler A, Lauer ME, Ringler P, Kobold S, Endres S, Klein C, Brinkmann U
Biological Chemistry 2022
Exploiting protease activation for therapy
Bleuez C, Koch WF, Urbach C, Hollfelder F, Jermutus L
Drug Discovery Today 2022
Mechanistic insights into the rational design of masked antibodies
Orozco CT, Bersellini M, Irving LM, Howard WW, Hargreaves D, Devine PW, Siouve E, Browne GJ, Bond NJ, Phillips JJ, Ravn P, Jackson SE
mAbs 2022
A comprehensive prognostic and immune analysis of enhancer RNA identifies IGFBP7-AS1 as a novel prognostic biomarker in Uterine Corpus Endometrial Carcinoma
Liu J, Yin J, Wang Y, Cai L, Geng R, Du M, Zhong Z, Ni S, Huang X, Yu H, Bai J
Biological Procedures Online 2022
An immune-related gene prognostic risk index for pancreatic adenocarcinoma
Su Y, Qi R, Li L, Wang X, Li S, Zhao X, Hou R, Ma W, Liu D, Zheng J, Shi M
Frontiers in immunology 2022
A novel tumor mutational burden-based risk model predicts prognosis and correlates with immune infiltration in ovarian cancer
Wang H, Liu J, Yang J, Wang Z, Zhang Z, Peng J, Wang Y, Hong L
Frontiers in immunology 2022
A comprehensive pan-cancer analysis of the expression characteristics, prognostic value, and immune characteristics of TOP1MT
Fei L, Lu Z, Xu Y, Hou G
Frontiers in Genetics 2022
CTLA4-Linked Autoimmunity in the Pathogenesis of Endometriosis and Related Infertility: A Systematic Review.
Mikuš M, Goldštajn MŠ, Brlečić I, Dumančić S, Laganà AS, Chiantera V, Vujić G, Ćorić M
International journal of molecular sciences 2022
Comprehensive analysis of SLC43A2 on the tumor immune microenvironment and prognosis of liver hepatocellular carcinoma
Liao Y, Weng J, Chen L, Hu N, Yuan X, Wang J, He F, Cai Y, Huang Q, Wang J, Huang L
Frontiers in Genetics 2022
Construction of a competing endogenous RNA network in head and neck squamous cell carcinoma by pan-cancer analysis
Zheng D, Luo S, Wang S, Huang J, Zhou Y, Su L, Chen Z, Wang S, He W
Translational cancer research 2022
A CD8+ T cell-associated immune gene panel for prediction of the prognosis and immunotherapeutic effect of melanoma
Sun S, Zhi Z, Su Y, Sun J, Li Q
Frontiers in immunology 2022
Current landscape and future directions of bispecific antibodies in cancer immunotherapy
Wei J, Yang Y, Wang G, Liu M
Frontiers in immunology 2022
Distinct Dynamics of Migratory Response to PD-1 and CTLA-4 Blockade Reveals New Mechanistic Insights for Potential T-Cell Reinvigoration following Immune Checkpoint Blockade
Safaeifard F, Goliaei B, Aref AR, Foroughmand-Araabi MH, Goliaei S, Lorch J, Jenkins RW, Barbie DA, Shariatpanahi SP, Rüegg C
Cells 2022
Treatments for resectable esophageal cancer: from traditional systemic therapy to immunotherapy
Yan Y, Feng X, Li C, Lerut T, Li H
Chinese Medical Journal 2022
FOXP3+ regulatory T cells and the immune escape in solid tumours
Qiu Y, Ke S, Chen J, Qin Z, Zhang W, Yuan Y, Meng D, Zhao G, Wu K, Li B, Li D
Frontiers in immunology 2022
Identification and Verification of an Alternative Polyadenylation-Related lncRNA Prognostic Signature for Glioma.
Wang H, Jiang Z
Computational and mathematical methods in medicine 2022
Targeting the spectrum of immune checkpoints in prostate cancer
LA Sena, SR Denmeade, ES Antonarakis
Expert Review of Clinical Pharmacology 2021
Generation of vascular chimerism within donor organs
S Cohen, S Partouche, M Gurevich, V Tennak, V Mezhybovsky, D Azarov, S Soffer-Hirschberg, B Hovav, H Niv-Drori, C Weiss, A Borovich, G Cohen, A Wertheimer, G Shukrun, M Israeli, V Yahalom, D Leshem-Lev, L Perl, R Kornowski, A Wiznitzer, A Tobar, M Feinmesser, E Mor, E Atar, E Nesher
Scientific Reports 2021
CTLA-4 in Regulatory T Cells for Cancer Immunotherapy
N Sobhani, DR Tardiel-Cyril, A Davtyan, D Generali, R Roudi, Y Li
Cancers 2021
In Vivo Measurement of Granzyme Proteolysis from Activated Immune Cells with PET
N Zhao, C Bardine, AL Lourenço, Y Wang, Y Huang, SJ Cleary, DM Wilson, DY Oh, L Fong, MR Looney, MJ Evans, CS Craik
ACS Central Science 2021
Tumor-conditional IL-15 pro-cytokine reactivates anti-tumor immunity with limited toxicity
J Guo, Y Liang, D Xue, J Shen, Y Cai, J Zhu, YX Fu, H Peng
Cell Research 2021
Current Progress and Future Perspectives of Immune Checkpoint in Cancer and Infectious Diseases
X Cai, H Zhan, Y Ye, J Yang, M Zhang, J Li, Y Zhuang
Frontiers in Genetics 2021
Immune-Related Genes to Construct a Novel Prognostic Model of Breast Cancer: A Chemosensitivity-Based Study
ZM Deng, W Hu, FF Dai, MQ Yuan, M Hu, YX Cheng
Frontiers in immunology 2021
Chemoresistance and Metastasis in Breast Cancer Molecular Mechanisms and Novel Clinical Strategies
J Cao, M Zhang, B Wang, L Zhang, F Zhou, M Fang
Frontiers in Oncology 2021
Next generation of tumor-activating type I IFN enhances anti-tumor immune responses to overcome therapy resistance
X Cao, Y Liang, Z Hu, H Li, J Yang, EJ Hsu, J Zhu, J Zhou, YX Fu
Nature Communications 2021
Switchable immune modulator for tumor-specific activation of anticancer immunity
Y Zhao, YQ Xie, SV Herck, S Nassiri, M Gao, Y Guo, L Tang
Science Advances 2021
Intratumoral DNA-based delivery of checkpoint-inhibiting antibodies and interleukin 12 triggers T cell infiltration and anti-tumor response
L Jacobs, L Yshii, S Junius, N Geukens, A Liston, K Hollevoet, P Declerck
Cancer Gene Therapy 2021
The yin and yang of co-inhibitory receptors: toward anti-tumor immunity without autoimmunity
A Schnell, L Bod, A Madi, VK Kuchroo
Cell Research 2020
Modulation of regulatory T cell function and stability by co-inhibitory receptors
LE Lucca, M Dominguez-Villar
Nature Reviews Immunology 2020
Re-education of the Tumor Microenvironment With Targeted Therapies and Immunotherapies
SF Ngiow, A Young
Frontiers in immunology 2020
Thymosin α1 protects from CTLA-4 intestinal immunopathology
G Renga, MM Bellet, M Pariano, M Gargaro, C Stincardini, F DOnofrio, P Mosci, S Brancorsini, A Bartoli, AL Goldstein, E Garaci, L Romani, C Costantini
2020
Inducers, Attractors and Modulators of CD4+ Treg Cells in Non-Small-Cell Lung Cancer
M Xie, J Wei, J Xu
Frontiers in immunology 2020
Molecular mechanism for impaired suppressive function of Tregs in autoimmune diseases: A summary of cell‐intrinsic and cell‐extrinsic factors
L Yang, G Wang, H Xia
Journal of Cellular and Molecular Medicine 2020
Immunotherapy to treat malignancy in patients with pre-existing autoimmunity
P Boland, AC Pavlick, J Weber, S Sandigursky
Journal for ImmunoTherapy of Cancer 2020
Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule
A Berezhnoy, BJ Sumrow, K Stahl, K Shah, D Liu, J Li, SS Hao, AD Costa, S Kaul, J Bendell, GM Cote, JJ Luke, RE Sanborn, MR Sharma, F Chen, H Li, G Diedrich, E Bonvini, PA Moore
Reproduction 2020
Ab locks for improving the selectivity and safety of antibody drugs
WW Lin, YC Lu, CH Chuang, TL Cheng
Journal of Biomedical Science 2020
Oncolytic Virus Encoding a Master Pro-Inflammatory Cytokine Interleukin 12 in Cancer Immunotherapy
HM Nguyen, K Guz-Montgomery, D Saha
Cells 2020
Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody
M Geiger, KG Stubenrauch, J Sam, WF Richter, G Jordan, J Eckmann, C Hage, V Nicolini, A Freimoser-Grundschober, M Ritter, ME Lauer, H Stahlberg, P Ringler, J Patel, E Sullivan, S Grau-Richards, S Endres, S Kobold, P Umaña, P Brünker, C Klein
Nature Communications 2020
MRI of tumor T cell infiltration in response to checkpoint inhibitor therapy
X Jiang, S Dudzinski, KE Beckermann, K Young, E McKinley, OJ McIntyre, JC Rathmell, J Xu, JC Gore
Journal for ImmunoTherapy of Cancer 2020
Combinational immunotherapy based on immune checkpoints inhibitors in small cell lung cancer: is this the beginning to reverse the refractory situation?
H Guo, Y He, P Chen, L Wang, W Li, B Chen, Y Liu, H Wang, S Zhao, C Zhou
Journal of Thoracic Disease 2020
Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities
KE Pauken, M Dougan, NR Rose, AH Lichtman, AH Sharpe
Trends in Immunology 2019
Demystifying the manipulation of host immunity, metabolism, and extraintestinal tumors by the gut microbiome
Z Zhang, H Tang, P Chen, H Xie, Y Tao
Signal Transduction and Targeted Therapy 2019
Targeting Negative and Positive Immune Checkpoints with Monoclonal Antibodies in Therapy of Cancer
K Marhelava, Z Pilch, M Bajor, A Graczyk-Jarzynka, R Zagozdzon
Cancers 2019
Mechanisms of action for different checkpoint inhibitors
P Berraondo
HemaSphere 2019
An adapted anti-CTLA-4 therapeutic aimed at mitigating the toxicities of checkpoint inhibition
Jarushka Naidoo, Arbor Dykema, Franco D'Alessio
Journal of Clinical Investigation 2018
Pulmonary surfactant: an immunological perspective
ZC Chroneos, Z Sever-Chroneos, VL Shepherd
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 2009

← Previous 1 2 3 4 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Blogged by 1
Posted by 21 X users
Referenced in 1 patents
On 3 Facebook pages
112 readers on Mendeley
See more details